Immunic, inc. announces proposed public offering

New york , may 28, 2025 /prnewswire/ -- immunic, inc. ("immunic" or the "company") (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock, (ii) series a warrants to purchase shares of common stock (or pre-funded warrants) expiring on december 31, 2025, (iii) and series b warrants to purchase shares of common stock (or pre-funded warrants) expiring five years following the issuance date. the series a and b warrants will immediately expire in proportion to the extent that the corresponding pre-funded warrant offered hereby is exercised on or prior to september 30, 2025, subject to certain exceptions.
IMUX Ratings Summary
IMUX Quant Ranking